Chronic myeloproliferative disorders (CMPD) consisted of the disease with chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF) and other proliferative diseases have commonly developed increased megakaryocytes. Recently, clonal assay for megakaryocytic progenitors, identification of young megakaryocytes and isolation of megakaryocytes have been greatly facilitated an analysis of megakaryopoeisis. It is still difficult quantitatively and serially to estimate megakaryopoiesis in CMPD. However, number of CFU-Meg, number of megakaryocytes (PGPIIb/IIIb) in the clot section, cytoplasmic area and DNA content of megakaryocytes were measurable in the clinical materials. The present lecture has been focused to following points; 1) megakaryopoiesis in CML, 2) differences of megakaryopoiesis between ET and PV, 3) megakaryopoiesis in Ph1 positive ET, and 4) megakaryopoiesis in rective thrombocytosis by our data and previous studies.